NVS · Novartis
AI read · Good for NVS
The AI's read
This gives Novartis another group of patients who may be treated with an existing medicine. Cosentyx is described as the first and only anti-IL-17 biologic for this illness, giving it a distinct place. The source gives no sales estimate, but the added use favors the company.